
Cristina Federici

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/653580/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Microenvironmental pH Is a Key Factor for Exosome Traffic in Tumor Cells. Journal of Biological Chemistry, 2009, 284, 34211-34222.	3.4	1,207
2	High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients. PLoS ONE, 2009, 4, e5219.	2.5	806
3	Effect of Proton Pump Inhibitor Pretreatment on Resistance of Solid Tumors to Cytotoxic Drugs. Journal of the National Cancer Institute, 2004, 96, 1702-1713.	6.3	395
4	Exosome Release and Low pH Belong to a Framework of Resistance of Human Melanoma Cells to Cisplatin. PLoS ONE, 2014, 9, e88193.	2.5	300
5	Proton Pump Inhibitors Induce Apoptosis of Human B-Cell Tumors through a Caspase-Independent Mechanism Involving Reactive Oxygen Species. Cancer Research, 2007, 67, 5408-5417.	0.9	280
6	Cannibalism of Live Lymphocytes by Human Metastatic but Not Primary Melanoma Cells. Cancer Research, 2006, 66, 3629-3638.	0.9	242
7	Increased PSA expression on prostate cancer exosomes in inÂvitro condition and in cancer patients. Cancer Letters, 2017, 403, 318-329.	7.2	196
8	Exosomes from human colorectal cancer induce a tumor-like behavior in colonic mesenchymal stromal cells. Oncotarget, 2016, 7, 50086-50098.	1.8	124
9	Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 648-657.	5.2	97
10	Effect Of Human Natural Killer and γδT Cells on the Growth of Human Autologous Melanoma Xenografts in SCID Mice. Cancer Research, 2004, 64, 378-385.	0.9	90
11	Natural-Killer-Derived Extracellular Vesicles: Immune Sensors and Interactors. Frontiers in Immunology, 2020, 11, 262.	4.8	87
12	Exosomes: the ideal nanovectors for biodelivery. Biological Chemistry, 2013, 394, 1-15.	2.5	79
13	The human homologue of <i>Dictyostelium discoideum</i> phg1A is expressed by human metastatic melanoma cells. EMBO Reports, 2009, 10, 1348-1354.	4.5	57
14	Pâ€glycoprotein binds to ezrin at amino acid residues 149–242 in the FERM domain and plays a key role in the multidrug resistance of human osteosarcoma. International Journal of Cancer, 2012, 130, 2824-2834.	5.1	56
15	Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma. Cancer Letters, 2016, 376, 278-283.	7.2	56
16	Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 119-125.	5.2	54
17	Identification and Relevance of the CD95-binding Domain in the N-terminal Region of Ezrin. Journal of Biological Chemistry, 2004, 279, 9199-9207.	3.4	53
18	Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 538-545.	5.2	47

CRISTINA FEDERICI

#	Article	IF	CITATIONS
19	Pleiotropic function of ezrin in human metastatic melanomas. International Journal of Cancer, 2009, 124, 2804-2812.	5.1	41
20	Potential Role for IL-7 in Fas-Mediated T Cell Apoptosis During HIV Infection. Journal of Immunology, 2007, 178, 5340-5350.	0.8	40
21	Detection of exosomal prions in blood by immunochemistry techniques. Journal of General Virology, 2015, 96, 1969-1974.	2.9	37
22	CD95/phosphorylated ezrin association underlies HIV-1 GP120/IL-2-induced susceptibility to CD95(APO-1/Fas)-mediated apoptosis of human resting CD4+T lymphocytes. Cell Death and Differentiation, 2004, 11, 574-582.	11.2	32
23	The Fatty Acid and Protein Profiles of Circulating CD81-Positive Small Extracellular Vesicles Are Associated with Disease Stage in Melanoma Patients. Cancers, 2021, 13, 4157.	3.7	17
24	Lipidic Profile Changes in Exosomes and Microvesicles Derived From Plasma of Monoclonal Antibody-Treated Psoriatic Patients. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	17
25	Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase. Oncotarget 2017 8, 4147-4155	1.8	12